Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Atrial flutter is similar to atrial fibrillation ... and rapid ventricular heart rates, both of which may reduce the ability to increase cardiac output and, particularly when AF occurs in the ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Breast cancer is the most common cancer among women in several countries around the world, including Japan, where 1 in 9 ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

Sky Labs' CART-I ring – described as a cardio tracker – achieved 84.6% sensitivity compared to 69.1% for the Apple Watch, ...

Several ASX-listed medtech companies are delivering technologies that enhance clinical precision, safety, and efficiency in healthcare.